1 week Ago By ABMN Staff
Wells Fargo & Company MN cut its position in Immunocore Holdings plc ( NASDAQ:IMCR – Free Report ) by 13.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,935 shares of the company’s stock after selling 11,120 shares during the quarter.
Wells Fargo & Company MN’s holdings in Immunocore were worth $2,122,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of Immunocore by 63.
9% in the third quarter. State Street Corp now owns 76,671 shares of the company’s stock valued at $2,387,000 after acquiring an additional 29,897 shares during the period. Principal Financial Group Inc.
raised its stake in Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc.
now owns 546,318 shares of the company’s stock worth $17,007,000 after purchasing an additional 109,206 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in Immunocore by 125.
4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock valued at $1,463,000 after purchasing an additional 27,598 shares during the period.
Crossmark Global Holdings Inc. grew its position in shares of Immunocore by 36.7% during the 4th quarter.
Crossmark Global Holdings Inc. now owns 38,020 shares of the company’s stock worth $1,121,000 after purchasing an additional 10,217 shares in the last quarter. Finally, Primecap Management Co.
CA increased its holdings in shares of Immunocore by 8.0% during the fourth quarter. Primecap Management Co.
CA now owns 2,668,550 shares of the company’s stock worth $78,722,000 after purchasing an additional 196,530 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.
Insider Activity In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of the stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $29.
72 per share, with a total value of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.
20. This trade represents a 60.40 % increase in their ownership of the stock.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . 10.40% of the stock is owned by corporate insiders.
Immunocore Trading Down 0.7 % Analysts Set New Price Targets IMCR has been the topic of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and set a $71.
00 price target on shares of Immunocore in a research report on Thursday, April 10th. JPMorgan Chase & Co. reduced their target price on Immunocore from $54.
00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, April 14th. Morgan Stanley restated an “equal weight” rating and issued a $35.
00 price target on shares of Immunocore in a research report on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Wednesday, March 12th.
Finally, Mizuho decreased their target price on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a report on Monday, April 7th.
One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.90.
View Our Latest Research Report on IMCR Immunocore Profile ( Free Report ) Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Recommended Stories Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings plc ( NASDAQ:IMCR – Free Report ). Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.
com's FREE daily email newsletter ..
